Feasibility of HLA-Haploidentical Hematopoietic Stem Cell Transplantation With Post-Transplantation Cyclophosphamide for Advanced Pediatric Malignancies

REFERENCES

• Ogawa H, Ikegame K, Kaida K, Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) bone marrow transplantation using only pharmacological GVHD prophylaxis. Exp Hematol. 2008;36:1–8.
   PubMed Web of Science ®Google Scholar
• Inoue M, Nakano T, Yoneda A, Graft-versus-tumor effect in a patient with advanced neuroblastoma who received HLA haplo-identical bone marrow transplantation. Bone Marrow Transplant. 2003;32:103–106.
   Google Scholar
• Koscielniak E, Gross-Wieltsch U, Treuner J, Graft-versus-Ewing sarcoma effect and long-term remission induced by haploidentical stem-cell transplantation in a patient with relapse of metastatic disease. J Clin Oncol. 2005;23:242–244.
   PubMed Web of Science ®Google Scholar
• Aversa F, Terenzi A, Tabilio A, Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol. 2005;23:3447–3454.
   PubMed Web of Science ®Google Scholar
• Lu DP, Dong L, Wu T, Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood. 2006;107:3065–3073.
   PubMed Web of Science ®Google Scholar
• Huang XJ, Liu DH, Liu KY, Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant. 2006;38:291–297.
   PubMed Web of Science ®Google Scholar
• O'Donnell PV, Luznik L, Jones RJ, Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2002;8:377–836.
   PubMed Web of Science ®Google Scholar
• Luznik L, O'Donnell PV, Symons HJ, HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14:641–650.
   PubMed Web of Science ®Google Scholar
• Ciurea SO, Mulanovich V, Saliba RM, Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012;18:1835–1844.
   PubMed Web of Science ®Google Scholar
• Raiola AM, Dominietto A, Ghiso A, Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. Biol Blood Marrow Transplant. 2013;19:117–122.
   PubMed Web of Science ®Google Scholar
• Solomon SR, Sizemore CA, Sanacore M, Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial. Biol Blood Marrow Transplant. 2012;18:1859–1866.
   PubMed Web of Science ®Google Scholar
• http://evs.nci.nih.gov/ftp1/CTCAE/About.html
   Google Scholar
• Oken MM, Creech RH, Tormey DC, Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–655.
   PubMed Web of Science ®Google Scholar
• Takagi S, Masuoka K, Uchida N, High incidence of haemophagocytic syndrome following umbilical cord blood transplantation for adults. Br J Haematol. 2009;147:543–553.
   PubMed Web of Science ®Google Scholar
• Koyama M, Sawada A, Yasui M, Encouraging results of low-dose etoposide in the treatment of early-onset hemophagocytic syndrome following allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2007;86:466–467.
   Google Scholar
• Sawada A, Koyama-Sato M, Yasui M, Multiplex polymerase chain reaction for six herpesviruses after hematopoietic stem cell transplantation. Pediatr Int. 2011;53:1010–1017.
   Google Scholar
• Przepiorka D, Weisdorf D, Martin P, Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15:825–828.
   Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–216.
   PubMed Web of Science ®Google Scholar
• Inoue M, Okamura T, Yasui M, Increased intensity of acute graft-versus-host disease after reduced-intensity bone marrow transplantation compared to conventional transplantation from an HLA-matched sibling in children. Bone Marrow Transplant. 2006;37:601–605.
   Google Scholar
• Inoue M, Yasui M, Sawada A, Encouraging results of stem cell transplantation following a melphalan-preceding intensified preparative regimen for refractory acute leukemia in children. Rinsho Ketsueki. 2007;48:1470–1477.
   Google Scholar
• Kobbe G, Fenk R, Neumann F, Transplantation of allogeneic CD34+-selected cells followed by early T-cell add-backs: favorable results in acute and chronic myeloid leukemia. Cytotherapy. 2004;6:533–542.
   PubMed Web of Science ®Google Scholar
• Martelli MF, Di Ianni M, Ruggeri L, HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse. Blood. 2014;124:638–644.
   PubMed Web of Science ®Google Scholar
• Grosso D, Carabasi M, Filicko-O'Hara J, A 2-step approach to myeloablative haploidentical stem cell transplantation: a phase 1/2 trial performed with optimized T-cell dosing. Blood. 2011;118:4732–4739.
   PubMed Web of Science ®Google Scholar
• Miyakoshi S, Yuji K, Kami M, Successful engraftment after reduced-intensity umbilical cord blood transplantation for adult patients with advanced hematological diseases. Clin Cancer Res. 2004;10:3586–3592.
   PubMed Web of Science ®Google Scholar
• Kakodkar NC, Peddinti RR, Tian Y, Sorafenib inhibits neuroblastoma cell proliferation and signaling, blocks angiogenesis, and impairs tumor growth. Pediatr Blood Cancer. 2012;59:642–647.
   PubMed Web of Science ®Google Scholar
• Yamada K, Yasui M, Kondo O, Feasibility of reduced-intensity allogeneic stem cell transplantation with imatinib in children with philadelphia chromosome-positive acute lymphoblastic leukemia. Pediatr Blood Cancer. 2013;60:E60–E62.
   Google Scholar
• Adriana S, Valeria CG, Roseane G, Haploidentical hematopoietic stem cell transplantation with reduced intensity conditioning, T-cell replete grafts and post-transplant cyclophosphamide in pediatrics. Blood. 2013;122:5510.
   Google Scholar